Congress

Gray Promotes Peter Zampa to Senior National Correspondent

Retrieved on: 
Thursday, April 4, 2024
Boston University, ESPN, NBC, United, International, Congress, Comcast, Broadcast journalism, United Nations, News

ATLANTA, April 04, 2024 (GLOBE NEWSWIRE) -- Gray Television, Inc. (“Gray”) (NYSE: GTN) announced today the promotion of Peter Zampa to Senior National Correspondent for the Gray Television Washington News Bureau.

Key Points: 
  • ATLANTA, April 04, 2024 (GLOBE NEWSWIRE) -- Gray Television, Inc. (“Gray”) (NYSE: GTN) announced today the promotion of Peter Zampa to Senior National Correspondent for the Gray Television Washington News Bureau.
  • In his new role, Peter will be based in New York City covering the local impact of national and international stories for Gray affiliates, including Wall Street and the United Nations.
  • “Our viewers trust Gray to provide fair and unbiased reporting with a distinctly local perspective,” Gray’s Chief Operating Officer Sandy Breland said.
  • “Peter is a relatable storyteller who understands how to connect national headlines with viewers’ concerns in each of our markets,” said General Manager of Gray’s Washington Operations Lisa Allen.

Samba TV Unveils Real-Time Ad Targeting for Political Advertisers to Respond Quickly to Shifting Voter Audiences

Retrieved on: 
Thursday, April 4, 2024
DMA's, Season, Congress, Samba TV, White, SAN, History, News, Yahoo!, TelevisaUnivision, Product management, Product strategy

Yahoo and TelevisaUnivision, two early adopters of the new solution, have integrated Samba TV’s innovative near-real time political audience segments to better empower political advertisers on their platforms.

Key Points: 
  • Yahoo and TelevisaUnivision, two early adopters of the new solution, have integrated Samba TV’s innovative near-real time political audience segments to better empower political advertisers on their platforms.
  • Samba TV’s Real Time Political Audiences facilitates the next day activation of digital campaigns to reach key voter groups with time-sensitive political messaging.
  • Advertisers can now build customized political ad exposure segments and launch their targeted campaign the next day, the quickest turnaround in the industry.
  • This game-changing capability ensures political advertisers are targeting the right voters in the most efficient and effective method possible.

Parexel Named “Best Contract Research Organization” at 17th Annual Vaccine Industry Excellence (ViE) Awards

Retrieved on: 
Thursday, April 4, 2024
ChromeOS, Congress, Infection, Vie, Global health, Vaccine, MD, Senior, Master of Science, Parexel, Physician, Terrapin, Pharmaceutical industry

DURHAM, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been named “Best Contract Research Organization” at the 17th Annual Vaccine Industry Excellence (ViE) Awards.

Key Points: 
  • DURHAM, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been named “Best Contract Research Organization” at the 17th Annual Vaccine Industry Excellence (ViE) Awards.
  • Winners were named across 13 categories, including Best Contract Research Organization, which recognizes the role of CROs in supporting the development of safe and effective vaccines.
  • The annual ViE Awards, organized by Terrapin, celebrate the industry’s most outstanding achievements and showcase excellence in the global vaccine industry.
  • Parexel was recognized at the ViE Awards ceremony during the World Vaccine Congress on April 2 in Washington, D.C.

Media Advisory: Budget 2024 Must Invest in Affordability, Reject Austerity

Retrieved on: 
Thursday, April 4, 2024
Pension, Family, Unemployment benefits, Congress, EI, Comment, Bruske, Government

OTTAWA, April 04, 2024 (GLOBE NEWSWIRE) -- Bea Bruske, President of the Canadian Labour Congress, is available for comment on what workers are looking for in the upcoming federal budget.

Key Points: 
  • OTTAWA, April 04, 2024 (GLOBE NEWSWIRE) -- Bea Bruske, President of the Canadian Labour Congress, is available for comment on what workers are looking for in the upcoming federal budget.
  • The upcoming budget is an opportunity to deliver much-needed help and address these inequities,” explained Bruske.
  • “We must invest in non-profit rental and social housing, to make homes affordable for every family.
  • “Budget 2024 is an opportunity to fight back against a vision of Canada where wealthy corporations get more tax giveaways, and deeper government spending cuts mean even less help for people who need it most.”

SK hynix announces semiconductor advanced packaging investment in Purdue Research Park

Retrieved on: 
Wednesday, April 3, 2024
CHIPS, Second Continental Congress, HBM, Congress, MediaTek, Federation, Partnership, Technology policy, SK Hynix, Saab, Research, I-65, News, Rolls-Royce, AI, Social responsibility, Semiconductor, Bayer, Silicon, Workforce, ChatGPT, Purdue Research Park, Policy

WEST LAFAYETTE, Ind., April 03, 2024 (GLOBE NEWSWIRE) -- SK hynix Inc. announced Wednesday (April 3) that it plans to invest close to $4 billion to build an advanced packaging fabrication and R&D facility for AI products in the Purdue Research Park.

Key Points: 
  • WEST LAFAYETTE, Ind., April 03, 2024 (GLOBE NEWSWIRE) -- SK hynix Inc. announced Wednesday (April 3) that it plans to invest close to $4 billion to build an advanced packaging fabrication and R&D facility for AI products in the Purdue Research Park.
  • “We are excited to build a state-of-the-art advanced packaging facility in Indiana,” said SK hynix CEO Kwak Noh-Jung.
  • “SK hynix is the global pioneer and dominant market leader in memory chips for AI,” Purdue President Mung Chiang said.
  • This historic announcement is the next step in Purdue University’s persistent pursuit of semiconductor excellence as part of the Purdue Computes initiative.

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Retrieved on: 
Wednesday, April 3, 2024
ART, IgA nephropathy, Congress, Quality of life (healthcare), Patient, SAN, Kidney failure, Immunoglobulin A, RAAS, FSGS, PROTECT, Focal segmental glomerulosclerosis, Abstract, Kidney disease, Therapy, WCN, Proteinuria, ANNA, Communications satellite

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.

Key Points: 
  • SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.
  • At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria.
  • At ANNA, the Company will present additional insights from the HONUS trial, including health-related quality of life (HRQoL) data and the humanistic burden experienced by patients with IgAN and focal segmental glomerulosclerosis (FSGS).
  • “The data we are presenting at WCN and ANNA reinforce the wealth of evidence supporting FILSPARI’s profile to become an effective foundational treatment replacing RAAS inhibition, with the potential to reduce the lifetime risk of kidney failure for patients with IgAN,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.

Tennessee English as a Second Language Teacher Named 2024 National Teacher of the Year

Retrieved on: 
Wednesday, April 3, 2024
Equitable, University, Education, Congress, Biography, Rogersville, Tennessee, Knowledge, East Tennessee State University, ETS, Smarter Balanced Assessment Consortium, Student, Council, Teacher, ESL, Heart, Curriculum, VOYA, Language, Selection Committee, AIR, Defense, NWEA, Missy, Human, Tutoring

WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- The Council of Chief State School Officers (CCSSO) today announced Missy Testerman, a kindergarten through eighth grade English as a second language (ESL) teacher, as the 2024 National Teacher of the Year.

Key Points: 
  • WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- The Council of Chief State School Officers (CCSSO) today announced Missy Testerman, a kindergarten through eighth grade English as a second language (ESL) teacher, as the 2024 National Teacher of the Year.
  • She knows families are extensions of the classroom and often advocates for her families who speak little English.
  • As the 2024 National Teacher of the Year, Testerman will spend a year representing educators and serving as an ambassador for students and teachers across the nation.
  • From that group, the National Teacher of the Year is chosen by a Selection Committee composed of 16 individuals and education organizations.

Bankruptcy Filings Increase Across All Chapters in First Quarter 2024

Retrieved on: 
Tuesday, April 2, 2024
Bankruptcy, Congress, ABI, Dive (Belgian band), Housing, Task force, Calendar, Cryptocurrency

Total overall commercial bankruptcies increased 22 percent in the first quarter of 2024, as the 7,113 filings surpassed the 5,820 commercial filings during the first quarter of 2023.

Key Points: 
  • Total overall commercial bankruptcies increased 22 percent in the first quarter of 2024, as the 7,113 filings surpassed the 5,820 commercial filings during the first quarter of 2023.
  • The 120,094 total bankruptcy filings represented a 14 percent increase from the 105,497 total filings during the same period last year.
  • Consumer filings increased 13 percent, to 112,981 filings in the first quarter of 2024 from the 99,677 consumer filings during the same period in 2023.
  • Individual chapter 7 filings during the first quarter of 2024 were 66,861, a 17 percent increase over the 57,158 individual chapter 7 filings during the same period in 2023.

Envoy Medical Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 2, 2024
House, Growth, Congress, Patient, COCH, EFS, Classification, Hope, Esteem, Business analyst, Insurance, Kool-Aid, Clinical trial, Patent, Medicare, Marketing, CMS, Hearing, Representative

WHITE BEAR LAKE, Minn., April 02, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Completed Business Combination transaction at the end of September and began trading on Nasdaq under its own ticker, COCH, the first week of October 2023.
  • Early Feasibility Study (EFS) continues to meet milestones with all three implanted patients surpassing twelve-month post-activation visits remaining implanted.
  • Sales and marketing expenses increased $0.8 million for the year ended December 31, 2023 compared to the same period in 2022.
  • The increase is primarily due to a $2.8 million rise in professional and legal fees in 2023 related to the finalization of the Business Combination in the third quarter of 2023.

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

Retrieved on: 
Tuesday, April 2, 2024
IgA nephropathy, Atacicept, Congress, Immunoglobulin A, Persistent, Therapy, Pharmaceutical industry

BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be made at the 61st European Renal Association Congress (ERA24), which is taking place May 23—26, 2024, both virtually and in Stockholm.

Key Points: 
  • BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be made at the 61st European Renal Association Congress (ERA24), which is taking place May 23—26, 2024, both virtually and in Stockholm.
  • Phase 2b ORIGIN Study Open Label Extension with Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria: Week 72 Interim Analysis